ClinicalTrialsFinder

Tumor Clinical Trials in Seattle, Washington

102 recruitingSeattle, Washington

Showing 1–20 of 102 trials

Recruiting
Phase 2

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Solid TumorsHER2 Mutation
Bayer111 enrolled54 locationsNCT06760819
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled53 locationsNCT06253871
Recruiting
Phase 1

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Breast CancerAdvanced Solid Tumor
BeOne Medicines86 enrolled27 locationsNCT07222267
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Phase 1Phase 2

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 1

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Breast CancerUrothelial CarcinomaSoft Tissue Sarcoma+2 more
Avacta Life Sciences Ltd158 enrolled9 locationsNCT04969835
Recruiting
Phase 2

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled85 locationsNCT06172478
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 1Phase 2

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Advanced Breast CancerAdvanced Solid Tumors
Ensem Therapeutics233 enrolled15 locationsNCT06993844
Recruiting
Phase 1Phase 2

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled33 locationsNCT06726148
Recruiting
Phase 1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled36 locationsNCT06625775
Recruiting
Phase 1Phase 2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1Phase 2

SMP-3124LP in Adults With Advanced Solid Tumors

Solid Tumor
Sumitomo Pharma America, Inc.120 enrolled10 locationsNCT06526819
Recruiting
Phase 1

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Breast CancerOvarian CancerProstate Cancer+8 more
Clasp Therapeutics, Inc.90 enrolled21 locationsNCT06778863
Recruiting
Phase 1

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Breast CancerColorectal, CancerOvarian Cancer+6 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Phase 1Phase 2

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

HER2-positive Advanced Solid Tumor
DualityBio Inc.796 enrolled102 locationsNCT05150691
Recruiting
Phase 2

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca468 enrolled123 locationsNCT04482309
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Triple-Negative Breast CancerColorectal, CancerLung Cancer+14 more
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793
Recruiting
Phase 1

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Breast CancerAdvanced CancerAdvanced Solid Tumors+1 more
OnKure, Inc.200 enrolled34 locationsNCT06239467
Recruiting
Early Phase 1

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Solid Tumor
Presage Biosciences15 enrolled12 locationsNCT04541108